Although US stocks closed higher on Tuesday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
Joint Corp
- The Trade: The Joint Corp. JYNT 10% owner Jefferson Gramm acquired a total of 22,463 shares an average price of $13.03. To acquire these shares, it cost around $292,769.
- What’s Happening: Joint posted better-than-expected first-quarter earnings.
- What Joint Corp Does: The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sale of regional developer rights throughout the United States.
Nuvectis Pharma
- The Trade: Nuvectis Pharma, Inc. NVCT CEO and Chairman Ron Bentsur acquired a total of 260 shares at an average price of $15.52. To acquire these shares, it cost around $4,035.
- What’s Happening: Nuvectis Pharma recently announced FDA clearance of NXP900 IND.
- What Nuvectis Pharma Does: Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology.
Don’t forget to check out our premarket coverage here
Byrna Technologies
- The Trade: Byrna Technologies Inc. BYRN Chief Mktg and Rev Officer Luan Pham bought a total of 5,508 shares at an average price of $3.73. To acquire these shares, it cost around $20,547.
- What’s Happening: Byrna Technologies reported worse-than-expected second-quarter financial results and withdrew fiscal year 2023 guidance.
- What Byrna Technologies Does: Byrna Technologies Inc is a designer, manufacturer, retailer and distributor of technological solutions for security situations that do not require the use of lethal force.
Check This Out: Goldman Sachs Likely To Report Sharp Decline In Q2 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.